Patient Name
NAME_1
Report Date
29 March 2013
Diagnosis
Stomach GIST
Electronically Signed by NAME_2, Medical Director | CLIA Number: 22E2127531 | 29 March 2013
Netwri  Medicine, Inc., One Kendall Square Ste B3501, Cambridge MA | 1.888.988.3639 page 1 of 10
Date of Birth 21 December 1954 Client Cicily Medical
Center Specimen Received 28 March 2023
Gender Male Ordering Physician NAME_3 Specimen Site Not Provided
FMI Case # TRM001601 Additional Recipient NAME_4 Preyes Date of Collection 15 March 2013
Medical Record # 27528 FMI Client # 2411 Specimen Type Block
Specimen ID S11-2531 A4 Pathologist Not Provided
ABOUT THE TEST:
FoundationOne™ is a next-generation sequencing (NGS) based assay which identifies genomic alterations within hundreds of cancer-related genes.
PATIENT RESULTS TUMOR TYPE: STOMACH GIST
2 genomic alterations Genomic Alterations Identified†
NAME_5 Q556_V560del
CRKL amplification
Additional Disease-relevant Genes with No Reportable
Alterations Detected
PDGFRA
8 therapies associated with potential clinical benefit
0 therapies associated with lack of response
4 clinical trials
 †For a complete list of the genes assayed, please refer to the Appendix
THERAPEUTIC IMPLICATIONS
Genomic Alterations
 Detected
FDA Approved Therapies
(in patient’s tumor type)
FDA Approved Therapies
(in another tumor type) Potential Clinical Trials
NAME_5
Q556_V560del
Imatinib
Sunitinib
Dasatinib
Everolimus
Nilotinib
Pazopanib
Sorafenib
Temsirolimus
Yes, see clinical trials
section
CRKL
amplification
None Dasatinib Yes, see clinical trials
section
Note: Genomic alterations detected may be associated with activity of certain FDA approved drugs; however, the agents listed in this report may have
varied clinical evidence in the patient’s tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted
efficacy for this patient, nor are they ranked in order of level of evidence for this patient’s tumor type.
Patient Name
NAME_1
Report Date
29 March 2013
Diagnosis
Stomach GIST
Electronically Signed by NAME_2, Medical Director | CLIA Number: 22E2127531 | 29 March 2013
Netwri  Medicine, Inc., One Kendall Square Ste B3501, Cambridge MA | 1.888.988.3639 page 2 of 10
GENOMIC ALTERATIONS
GENE
ALTERATION
INTERPRETATION
NAME_5
Q556_V560del
The NAME_5 gene encodes the tyrosine kinase receptor NAME_5 (also known as c-NAME_5 or CD117), which is
expressed on the cell surface of a variety of cell types, including hematopoietic stem cells and
melanocytes. Binding of